



## WHAT IS CLAIMED IS:

1. A compound of formula I:



and pharmaceutically acceptable salts thereof, wherein  
 n is 0 or 1; m is 1, 2 or 3; R<sub>1</sub> is H, C<sub>1</sub>-C<sub>3</sub> alkyl, halogenated C<sub>1</sub>-C<sub>3</sub> alkyl or  
 cyclopropyl; R<sub>2</sub> is 4-chlorophenyl or 2,4,6-trichlorophenyl.

2. The compound of Claim 1 wherein n is 0.
3. The compound of Claim 1 wherein n is 1.
4. The compound of Claim 1 wherein m is 1.
5. The compound of Claim 1 wherein m is 2.
6. The compound of Claim 1 wherein R<sub>1</sub> is H.
7. The compound of Claim 1 wherein R<sub>1</sub> is CH<sub>3</sub>.
8. The compound of Claim 1 wherein R<sub>2</sub> is 4-chlorophenyl.
9. The compound of Claim 1 wherein R<sub>2</sub> is 2,4,6-trichlorophenyl.
10. The compound of Claim 1 having the stereoconfiguration  
 shown below:



11. The compound of Claim 10 wherein n is 0.
- 5 12. The compound of Claim 10 wherein n is 1.
13. The compound of Claim 10 wherein m is 1.
14. The compound of Claim 10 wherein m is 2.
- 10 15. The compound of Claim 10 wherein R<sub>1</sub> is H.
16. The compound of Claim 10 wherein R<sub>1</sub> is CH<sub>3</sub>.
- 15 17. The compound of Claim 10 wherein R<sub>2</sub> is 4-chlorophenyl.
18. The compound of Claim 10 wherein R<sub>2</sub> is 2,4,6-trichlorophenyl.
- 20 19. A compound selected from
  - [4-(4-chlorobenzyl)-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]-indol-3-yl]acetic acid,
  - {4-[1-(4-chlorophenyl)ethyl]-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl}acetic acid,
  - 25 [9-(4-chlorobenzyl)-6-fluoro-8-methanesulfonyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl]-acetic acid, and
  - [4-(4-chlorobenzyl)-7-fluoro-5-methanesulfonyl-1-oxo-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]acetic acid, or
  - a pharmaceutically acceptable salt thereof.

20. The compound (3R)-[4-(4-chlorobenzyl)-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid and pharmaceutically acceptable salts thereof.

5

21. The compound (+/-)-4-[1-(4-chlorophenyl)ethyl]-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl}acetic acid and pharmaceutically acceptable salts thereof.

10

22. The compound (+/-)-[9-(4-chlorobenzyl)-6-fluoro-8-methanesulfonyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid and pharmaceutically acceptable salts thereof.

15

23. The compound [4-(4-chlorobenzyl)-7-fluoro-5-methanesulfonyl-1-oxo-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]acetic acid and pharmaceutically acceptable salts thereof.

20

24. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

25. The composition of Claim 24 further comprising a second active ingredient selected from an antihistamine, a leukotriene antagonist and a leukotriene biosynthesis inhibitor.

25

26. A method for the treatment of prostaglandin D2 mediated diseases which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 1.

30

27. A method for the treatment of nasal congestion which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 1.

35

28. A method for the treatment of allergic asthma which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 1.

29. A method for the treatment of allergic rhinitis which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 1.